Fresenius SE ROA 2016-2024 | FSNUY
Current and historical return on assets (ROA) values for Fresenius SE (FSNUY) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| Fresenius SE ROA - Return on Assets Historical Data |
| Date |
TTM Net Income |
Total Assets |
Return on Assets |
| 2024-09-30 |
$-0.40B |
$46.59B |
-0.84% |
| 2024-06-30 |
$-1.20B |
$46.86B |
-2.13% |
| 2024-03-31 |
$-0.71B |
$48.08B |
-1.09% |
| 2023-12-31 |
$-0.64B |
$49.01B |
-0.87% |
| 2023-09-30 |
$0.27B |
$81.99B |
0.33% |
| 2023-06-30 |
$1.03B |
$83.32B |
1.26% |
| 2023-03-31 |
$1.35B |
$82.17B |
1.67% |
| 2022-12-31 |
$1.45B |
$80.51B |
1.78% |
| 2022-09-30 |
$1.77B |
$80.91B |
2.15% |
| 2022-06-30 |
$1.93B |
$81.00B |
2.33% |
| 2022-03-31 |
$2.09B |
$82.05B |
2.50% |
| 2021-12-31 |
$2.15B |
$85.14B |
2.56% |
| 2021-09-30 |
$2.07B |
$83.82B |
2.53% |
| 2021-06-30 |
$2.08B |
$83.93B |
2.58% |
| 2021-03-31 |
$1.97B |
$83.15B |
2.49% |
| 2020-12-31 |
$1.95B |
$76.13B |
2.53% |
| 2020-09-30 |
$2.03B |
$79.87B |
2.64% |
| 2020-06-30 |
$2.02B |
$76.59B |
2.68% |
| 2020-03-31 |
$2.10B |
$76.09B |
2.82% |
| 2019-12-31 |
$2.11B |
$75.05B |
2.85% |
| 2019-09-30 |
$2.12B |
$74.24B |
2.95% |
| 2019-06-30 |
$2.12B |
$72.98B |
3.04% |
| 2019-03-31 |
$2.37B |
$73.81B |
3.49% |
| 2018-12-31 |
$2.39B |
$66.97B |
3.64% |
| 2018-09-30 |
$2.41B |
$64.79B |
3.76% |
| 2018-06-30 |
$2.39B |
$65.57B |
3.76% |
| 2018-03-31 |
$2.10B |
$65.77B |
3.42% |
| 2017-12-31 |
$2.05B |
$60.06B |
3.44% |
| 2017-09-30 |
$1.93B |
$62.41B |
3.35% |
| 2017-06-30 |
$1.90B |
$58.18B |
3.52% |
| 2017-03-31 |
$1.85B |
$57.99B |
3.57% |
| 2016-12-31 |
$1.76B |
$51.40B |
3.59% |
| 2016-09-30 |
$1.68B |
$48.77B |
3.48% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Outpatient & Home Care |
$0.000B |
$23.628B |
|
Fresenius SE & Co is a health care company. It offers products and services for dialysis, hospitals and outpatient treatment. The company's business segment consists of Fresenius Medical Care is engaged in treating with chronic kidney failure; Fresenius Helios is a hospital operator; Fresenius Kabi supplies essential drugs, clinical nutrition products, medical devices and services and Fresenius Vamed plans, develops and manages healthcare facilities. Fresenius SE & Co is headquartered in Bad Homburg, Germany.
|
